ClinicalTrials.gg
CompletedNCT01054300Updated Nov 21, 2019Results posted

Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040)

A Phase 1 interventional study of Ertugliflozin 2 mg single dose and Ertugliflozin 2 mg split into twice daily in Diabetes Mellitus, Type 2 and Adult, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-11-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.

Enrollment
17th of 28
52 · median 83
Started
2010
with 4 others
Phase 1
8 of 28
none open now
Registered
2nd of 28
by date
Lead sponsor
18 of 28
Merck Sharp & Dohme LLC

Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 17th largest by enrollment, is one of 5 that started in 2010, is one of 8 in phase 1, and was the 2nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ertugliflozin

ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a Phase 1 randomized, double-blind, sponsor open, 4 arm, 2 way cross-over study using 2 cohorts. The objective of the study is to evaluate the pharmacodynamics (PD) effects and the pharmacokinetic (PK) of single day dosing of 2 mg and 4 mg doses of ertugliflozin (Ertu, PF-04971729/MK-8835) each administered once vs twice daily (morning [AM] and evening [PM]) in adults with type 2 diabetes.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Adult
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with type 2 diabetes mellitus, either treatment-naïve or on up to 2 acceptable oral anti-diabetes drugs for at least 8-weeks prior to study.

Exclusion criteria

Exclusion Criteria:

  • Participants with type 1 diabetes mellitus, participants with stroke, unstable angina, heart attack in last 6-months, uncontrolled blood pressure.
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Cohort 1: Ertu 2 mg/Placebo (Pbo)→Ertu 1 mg/Ertu 1 mg

    Period 1: Ertu 2 mg in the AM and Pbo in the PM for 1 day. Period 2: Ertu 1 mg in the AM and Ertu 1 mg in the PM for 1 day. There was a \>= 7 day washout period between Period 1 and Period 2.

    Drug: Ertugliflozin 2 mg single dose · Drug: Ertugliflozin 2 mg split into twice daily · Drug: Placebo

  • Experimental
    Cohort 1: Ertu 1 mg/Ertu 1 mg→Ertu 2 mg/Pbo

    Period 1: Ertu 1 mg in the AM and Ertu 1 mg in the PM for 1 day. Period 2: Ertu 2 mg in the AM and Pbo in the PM for 1 day. There was a \>= 7 day washout period between Period 1 and Period 2.

    Drug: Ertugliflozin 2 mg single dose · Drug: Ertugliflozin 2 mg split into twice daily · Drug: Placebo

  • Experimental
    Cohort 2: Ertu 4 mg/Pbo→Ertu 2 mg/Ertu 2 mg

    Period 1: Ertu 4 mg in the AM and Pbo in the PM for 1 day. Period 2: Ertu 2 mg in the AM and Ertu 2 mg in the PM for 1 day. There was a \>= 7 day washout period between Period 1 and Period 2.

    Drug: Ertugliflozin 4 mg single dose · Drug: Ertugliflozin 4 mg split into twice daily · Drug: Placebo

  • Experimental
    Cohort 2: Ertu 2 mg/Ertu 2 mg→Ertu 4 mg/Pbo

    Period 1: Ertu 2 mg in the AM and Ertu 2 mg in the PM for 1 day. Period 2: Ertu 4 mg in the AM and Pbo in the PM for 1 day. There was a \>= 7 day washout period between Period 1 and Period 2.

    Drug: Ertugliflozin 4 mg single dose · Drug: Ertugliflozin 4 mg split into twice daily · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Cumulative Urinary Glucose Excretion Over 0 to 24 Hours

    Urine for analysis of glucose was collected at prespecified intervals. Each participant emptied his/her bladder just before dosing, and the collection started after the morning dose (collection times: 0-4 hours, 4-8 hours, 8-12 hours, and 12-24 hours after the morning dose). The average amount of urinary glucose excreted from 0 to 24 hours after the morning dose is presented in the table below.

    Time frame: 0 to 24 hours after the morning dose

  2. Urinary Glucose Excretion by Time Period

    Urine for analysis of glucose was collected at prespecified intervals. Each participant emptied his/her bladder just before dosing, and the collection started after the morning dose (collection times: 0-4 hours, 4-8 hours, 8-12 hours, and 12-24 hours after the morning dose). The average amount of urinary glucose excreted during the pre-specified time frame is presented in the table below.

    Time frame: At 0-4 hrs, 4-8 hrs, 8-12 hrs, and 12-24 hrs after the AM dose (up to 24 hours)

  3. 24-hour Weighted Mean Plasma Glucose

    Blood was collected during each treatment period at pre-dose (fasted) on Day 1 (Hour 0) and post-dose (fed) on Day 1 at 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 12.5, 13, 14, 15, 16, 18, and 24 hours.

    Time frame: Up to 24 hours

  4. Weighted Mean Postprandial Plasma Glucose

    The weighted mean postprandial glucose over the specified intervals were analyzed by cohort.

    Time frame: At 0-5 hours, 5-12 hrs, and 12-18 hrs after the morning dose (up to 18 hours)

  5. Fasting Plasma Glucose

    Blood samples were to be collected following a fast from all food and drink (except water) for at least 8 hours. Fasting Plasma Glucose was collected as part of the assessment of weighted mean 24-hour plasma glucose. As such, it was not specified as an endpoint in the Statistical Analysis Plan and was not analyzed or summarized separately.

    Time frame: Up to 24 hours

  6. Fasting C-peptide

    The fasting c-peptide was analyzed by cohort using a mixed-effects model with sequence, period, and treatment as fixed effects and participant within sequence as a random effect.

    Time frame: Up to 24 hours (0 and 24 hours)

  7. Number of Participants Experiencing an Adverse Event

    An adverse event is any untoward medical occurrence in a clinical investigation participant administered a product or medical device. The table below includes all data collected since the first dose of study drug.

    Time frame: Up to 16 days

  8. Number of Participants Discontinuing Study Drug Due to an Adverse Event

    An adverse event is any untoward medical occurrence in a clinical investigation participant administered a product or medical device. The table below includes all data collected since the first dose of study drug. Data include participants discontinued due to adverse events, participants with dose reduced or temporary discontinuation due to adverse events.

    Time frame: Up to 8 days (Day 1 in each dosing period)

  9. Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUClast) for Ertugliflozin

    Pharmacokinetic (PK) parameter of AUClast for study drug. Actual sample collection times (relative to the AM dose) were used for the pharmacokinetic analysis.

    Time frame: 0 predose, 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 18, 24 hours postdose

  10. Maximum Plasma Concentration (Cmax) of Ertugliflozin

    PK parameter of Cmax for study drug. Actual sample collection times (relative to the AM dose) were used for the pharmacokinetic analysis.

    Time frame: 0 predose, 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 18, 24 hours postdose

  11. Time Taken to Reach the Maximum Observed Plasma Concentration (Tmax) of Ertugliflozin

    PK parameter of Tmax for study drug. Actual sample collection times (relative to the AM dose) were used for the pharmacokinetic analysis.

    Time frame: 0 predose, 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 18, 24 hours postdose

07

Results

Posted Nov 7, 2018

Participant flow

Period 1
Participant flow — Period 1
MilestoneCohort 1: Ertu 2 mg/Pbo→Ertu 1 mg/Ertu 1 mgCohort 1: Ertu 1 mg/Ertu 1 mg→Ertu 2 mg/PboCohort 2: Ertu 4 mg/Pbo→Ertu 2 mg/Ertu 2 mgCohort 2: Ertu 2 mg/Ertu 2 mg→Ertu 4 mg/P
Started13131313
Completed12131313
Not completed1000
Withdrew: Adverse event1000
Period 2
Participant flow — Period 2
MilestoneCohort 1: Ertu 2 mg/Pbo→Ertu 1 mg/Ertu 1 mgCohort 1: Ertu 1 mg/Ertu 1 mg→Ertu 2 mg/PboCohort 2: Ertu 4 mg/Pbo→Ertu 2 mg/Ertu 2 mgCohort 2: Ertu 2 mg/Ertu 2 mg→Ertu 4 mg/P
Started12131313
Completed12131213
Not completed0010
Withdrew: Withdrawal by subject0010

Outcome measures

PrimaryCumulative Urinary Glucose Excretion Over 0 to 24 Hours

Urine for analysis of glucose was collected at prespecified intervals. Each participant emptied his/her bladder just before dosing, and the collection started after the morning dose (collection times: 0-4 hours, 4-8 hours, 8-12 hours, and 12-24 hours after the morning dose). The average amount of urinary glucose excreted from 0 to 24 hours after the morning dose is presented in the table below.

Time frame:
0 to 24 hours after the morning dose
Reported as:
Least squares mean · Grams
Cumulative Urinary Glucose Excretion Over 0 to 24 Hours
GramsCohort 1: Ertugliflozin 1 mg Twice DailyCohort 1: Ertugliflozin 2 mg Once DailyCohort 2: Ertugliflozin 2 mg Twice DailyCohort 2: Ertugliflozin 4 mg Once Daily
Cumulative Urinary Glucose Excretion Over 0 to 24 Hours69.45 ± 9.0870.43 ± 9.0878.29 ± 9.7780.54 ± 9.81
PrimaryUrinary Glucose Excretion by Time Period

Urine for analysis of glucose was collected at prespecified intervals. Each participant emptied his/her bladder just before dosing, and the collection started after the morning dose (collection times: 0-4 hours, 4-8 hours, 8-12 hours, and 12-24 hours after the morning dose). The average amount of urinary glucose excreted during the pre-specified time frame is presented in the table below.

Time frame:
At 0-4 hrs, 4-8 hrs, 8-12 hrs, and 12-24 hrs after the AM dose (up to 24 hours)
Reported as:
Mean · Grams
Urinary Glucose Excretion by Time Period
GramsCohort 1: Ertugliflozin 1 mg Twice DailyCohort 1: Ertugliflozin 2 mg Once DailyCohort 2: Ertugliflozin 2 mg Twice DailyCohort 2: Ertugliflozin 4 mg Once Daily
0 to 4 hours post dose12.88 ± 14.6614.03 ± 11.6314.66 ± 11.8116.34 ± 10.16
4 to 8 hours post dose15.42 ± 12.0017.87 ± 12.6016.97 ± 11.6419.78 ± 14.02
8 to 12 hours post dose14.47 ± 8.8411.99 ± 7.7014.30 ± 10.5212.91 ± 6.93
12 to 24 hours post dose26.76 ± 20.1026.31 ± 21.1131.47 ± 22.7132.94 ± 21.08
Primary24-hour Weighted Mean Plasma Glucose

Blood was collected during each treatment period at pre-dose (fasted) on Day 1 (Hour 0) and post-dose (fed) on Day 1 at 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 12.5, 13, 14, 15, 16, 18, and 24 hours.

Time frame:
Up to 24 hours
Reported as:
Mean · mg/dL
24-hour Weighted Mean Plasma Glucose
mg/dLCohort 1: Ertugliflozin 1 mg Twice DailyCohort 1: Ertugliflozin 2 mg Once DailyCohort 2: Ertugliflozin 2 mg Twice DailyCohort 2: Ertugliflozin 4 mg Once Daily
24-hour Weighted Mean Plasma Glucose173.6 ± 26.94175.7 ± 29.88169.1 ± 35.91170.4 ± 41.26
PrimaryWeighted Mean Postprandial Plasma Glucose

The weighted mean postprandial glucose over the specified intervals were analyzed by cohort.

Time frame:
At 0-5 hours, 5-12 hrs, and 12-18 hrs after the morning dose (up to 18 hours)
Reported as:
Mean · mg/dL
Weighted Mean Postprandial Plasma Glucose
mg/dLCohort 1: Ertugliflozin 1 mg Twice DailyCohort 1: Ertugliflozin 2 mg Once DailyCohort 2: Ertugliflozin 2 mg Twice DailyCohort 2: Ertugliflozin 4 mg Once Daily
0 to 5 hours200.1 ± 38.27187.2 ± 41.37194.1 ± 46.87189.9 ± 53.17
5 to 12 hours159.4 ± 25.76159.8 ± 28.46160.5 ± 42.14161.5 ± 40.70
12 to 18 hours180.7 ± 35.98190.7 ± 35.38182.6 ± 40.79181.9 ± 40.79
PrimaryFasting Plasma Glucose

Blood samples were to be collected following a fast from all food and drink (except water) for at least 8 hours. Fasting Plasma Glucose was collected as part of the assessment of weighted mean 24-hour plasma glucose. As such, it was not specified as an endpoint in the Statistical Analysis Plan and was not analyzed or summarized separately.

Time frame:
Up to 24 hours

No measurements were reported for this outcome.

PrimaryFasting C-peptide

The fasting c-peptide was analyzed by cohort using a mixed-effects model with sequence, period, and treatment as fixed effects and participant within sequence as a random effect.

Time frame:
Up to 24 hours (0 and 24 hours)
Reported as:
Least squares mean · ng/mL
Fasting C-peptide
ng/mLCohort 1: Ertugliflozin 1 mg Twice DailyCohort 1: Ertugliflozin 2 mg Once DailyCohort 2: Ertugliflozin 2 mg Twice DailyCohort 2: Ertugliflozin 4 mg Once Daily
Fasting C-peptide2.82 ± 1.1482.76 ± 0.9973.00 ± 0.9162.99 ± 0.973
PrimaryNumber of Participants Experiencing an Adverse Event

An adverse event is any untoward medical occurrence in a clinical investigation participant administered a product or medical device. The table below includes all data collected since the first dose of study drug.

Time frame:
Up to 16 days
Reported as:
Count of participants · Participants
Number of Participants Experiencing an Adverse Event
ParticipantsCohort 1: Ertugliflozin 1 mg Twice DailyCohort 1: Ertugliflozin 2 mg Once DailyCohort 2: Ertugliflozin 2 mg Twice DailyCohort 2: Ertugliflozin 4 mg Once Daily
Number of Participants Experiencing an Adverse Event5835
PrimaryNumber of Participants Discontinuing Study Drug Due to an Adverse Event

An adverse event is any untoward medical occurrence in a clinical investigation participant administered a product or medical device. The table below includes all data collected since the first dose of study drug. Data include participants discontinued due to adverse events, participants with dose reduced or temporary discontinuation due to adverse events.

Time frame:
Up to 8 days (Day 1 in each dosing period)
Reported as:
Count of participants · Participants
Number of Participants Discontinuing Study Drug Due to an Adverse Event
ParticipantsCohort 1: Ertugliflozin 1 mg Twice DailyCohort 1: Ertugliflozin 2 mg Once DailyCohort 2: Ertugliflozin 2 mg Twice DailyCohort 2: Ertugliflozin 4 mg Once Daily
Number of Participants Discontinuing Study Drug Due to an Adverse Event0100
PrimaryArea Under the Plasma Concentration-time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUClast) for Ertugliflozin

Pharmacokinetic (PK) parameter of AUClast for study drug. Actual sample collection times (relative to the AM dose) were used for the pharmacokinetic analysis.

Time frame:
0 predose, 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 18, 24 hours postdose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUClast) for Ertugliflozin
ng*hr/mLCohort 1: Ertugliflozin 1 mg Twice DailyCohort 1: Ertugliflozin 2 mg Once DailyCohort 2: Ertugliflozin 2 mg Twice DailyCohort 2: Ertugliflozin 4 mg Once Daily
Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Time of the Last Quantifiable Concentration (AUClast) for Ertugliflozin131.8 ± 26132.7 ± 28272 ± 19270.5 ± 20
PrimaryMaximum Plasma Concentration (Cmax) of Ertugliflozin

PK parameter of Cmax for study drug. Actual sample collection times (relative to the AM dose) were used for the pharmacokinetic analysis.

Time frame:
0 predose, 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 18, 24 hours postdose
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) of Ertugliflozin
ng/mLCohort 1: Ertugliflozin 1 mg Twice DailyCohort 1: Ertugliflozin 2 mg Once DailyCohort 2: Ertugliflozin 2 mg Twice DailyCohort 2: Ertugliflozin 4 mg Once Daily
Maximum Plasma Concentration (Cmax) of Ertugliflozin19.51 ± 3926.98 ± 3734.80 ± 2350.83 ± 25
PrimaryTime Taken to Reach the Maximum Observed Plasma Concentration (Tmax) of Ertugliflozin

PK parameter of Tmax for study drug. Actual sample collection times (relative to the AM dose) were used for the pharmacokinetic analysis.

Time frame:
0 predose, 0.5, 1, 2, 3, 4, 5, 5.5, 6, 7, 8, 10, 12, 18, 24 hours postdose
Reported as:
Median · hours
Time Taken to Reach the Maximum Observed Plasma Concentration (Tmax) of Ertugliflozin
hoursCohort 1: Ertugliflozin 1 mg Twice DailyCohort 1: Ertugliflozin 2 mg Once DailyCohort 2: Ertugliflozin 2 mg Twice DailyCohort 2: Ertugliflozin 4 mg Once Daily
Time Taken to Reach the Maximum Observed Plasma Concentration (Tmax) of Ertugliflozin6.00 (0.500 to 12.0)1.00 (0.500 to 5.50)6.00 (0.500 to 8.00)1.00 (0.500 to 6.00)

Adverse events

Collected over Up to 16 days (including 7-day follow-up for each period). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Ertugliflozin 1 mg Twice Daily0/25 (0%)0/25 (0%)5/25 (20%)
Cohort 1: Ertugliflozin 2 mg Once Daily0/26 (0%)0/26 (0%)8/26 (30.8%)
Cohort 2: Ertugliflozin 2 mg Twice Daily0/26 (0%)0/26 (0%)3/26 (11.5%)
Cohort 2: Ertugliflozin 4 mg Once Daily0/26 (0%)0/26 (0%)5/26 (19.2%)
Most frequent other events
Showing 10 of 23
Most frequent other events
EventCohort 1: Ertugliflozin 1 mg Twice DailyCohort 1: Ertugliflozin 2 mg Once DailyCohort 2: Ertugliflozin 2 mg Twice DailyCohort 2: Ertugliflozin 4 mg Once Daily
HeadacheNervous system disorders3/253/261/262/26
DiarrhoeaGastrointestinal disorders0/250/261/263/26
DyspepsiaGastrointestinal disorders1/250/260/260/26
FatigueGeneral disorders1/251/260/260/26
Increased appetiteMetabolism and nutrition disorders1/250/260/260/26
Back painMusculoskeletal and connective tissue disorders1/250/260/260/26
Pain in extremityMusculoskeletal and connective tissue disorders1/251/260/260/26
Skin irritationSkin and subcutaneous tissue disorders1/250/260/260/26
Eye painEye disorders0/250/261/260/26
Vision blurredEye disorders0/251/260/260/26

Baseline characteristics

All randomized participants.

Age, Customized
Age, Customized(Participants)Cohort 1Cohort 2Total
18 - 44 years7714
45 - 64 years171835
65 years or older213
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2Total
Female437
Male222345
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Dawra VK, Liang Y, Shi H, Bass A, Hickman A, Terra SG, Zhou S, Cutler D, Sahasrabudhe V. A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects . Int J Clin Pharmacol Ther. 2019 Apr;57(4):207-216. doi: 10.5414/CP203343. PubMed 30802200 ↗
  • Fediuk DJ, Sahasrabudhe V, Dawra VK, Zhou S, Sweeney K. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1297-1306. doi: 10.1002/cpdd.970. Epub 2021 Jul 2. PubMed 34213819 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2010 to primary completion in Apr 2010, 1 month.

Results were first posted in Nov 2018, 8 years 7 months after primary completion.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 1 month is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2010
First posted
Jan 22, 2010
StartActual
Feb 17, 2010
Primary completionActual
Apr 7, 2010
CompletionActual
Apr 7, 2010
Results first posted
Nov 7, 2018
Last update
Nov 21, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01054300
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Jan 22, 2010
Start date
Feb 17, 2010
Primary completion
Apr 7, 2010
Completion
Apr 7, 2010
Results posted
Nov 7, 2018
Last update
Nov 21, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ertugliflozin

Start the discussion